Risedronate use may blunt appendicular lean mass loss secondary to sleeve gastrectomy: results from a pilot randomized controlled trial

Risedronate use may blunt appendicular lean mass loss secondary to sleeve gastrectomy: results from a pilot randomized controlled trial

Abstract Background Despite robust weight loss and cardiometabolic benefit, lean mass loss following sleeve gastrectomy (SG) confers health risk. Bisphosphonates are a potential therapeutic agent for lean mass maintenance. Thus, our objective was to explore the effect of 6 months of risedronate (vs....

Full description

Bibliographic Details
Main Authors: Laura E. Flores, Kristen M. Beavers, Daniel P. Beavers, Katelyn A. Greene, Diana A. Madrid, Ryan M. Miller, Jamy D. Ard, Laura D. Bilek, Ashley A. Weaver
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:JCSM Rapid Communications
Subjects:
Antiresorptive
Bariatric surgery
Body composition
Clinical trials
Dual‐energy x‐ray absorptiometry
Lean mass
Online Access:https://doi.org/10.1002/rco2.72

Internet

https://doi.org/10.1002/rco2.72

Similar Items